CDC-Derived Exosomes for Duchenne Heart Failure Fibrosis Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Duchenne muscular dystrophy-associated heart failure, including corticosteroids, fail to address the underlying pathophysiology of heart muscle loss and scar conversion, with no effective therapies available for late-stage patients, and heart transplantation is not an option due to exclusionary comorbidities.
Innovation Solution
Administration of cardiosphere-derived exosomes, isolated from serum-free media and characterized by specific markers, which contain a unique milieu of biological factors including cytokines, growth factors, and microRNAs, to treat heart failure by reducing fibrosis, inflammation, and promoting mitochondrial function and cardiomyogenesis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cardiosphere-derived cells are administered to treat heart failure, then regenerative effects and functional improvement occur, but device complexity and manufacturing difficulty increase
Solution Approach 1:
The patent extracts the therapeutic factors from the cardiosphere-derived cells by isolating exosomes secreted by these cells. The exosomes are separated from the parent cells through a multi-step process involving centrifugation and filtration, obtaining a concentrated exosome preparation that contains the regenerative factors without the complexity of living cell therapy
Solution Approach 2:
The patent creates a simplified copy of the cell therapy effect by using exosomes that replicate the regenerative function of the parent cells. The exosomes contain microRNAs and other biological factors that copy the therapeutic mechanism of cardiosphere-derived cells, achieving similar regenerative effects without requiring live cell administration
2Ease of manufacture
If conventional therapies are used for Duchenne muscular dystrophy heart failure, then treatment is simple, but therapeutic effectiveness is insufficient
Solution Approach 1:
The patent changes the therapeutic parameter from conventional small-molecule drugs to biologically active exosomes containing specific microRNAs. This parameter change enables the treatment to address the underlying pathophysiology of Duchenne muscular dystrophy heart failure while maintaining a relatively simple administration route (intravenous injection)
Solution Approach 2:
The patent uses a composite therapeutic approach by combining exosomes with specific microRNA cargo (including miR-1, miR-133, and miR-499) that targets multiple pathological pathways simultaneously. This composite structure allows the treatment to address fibrosis, inflammation, and mitochondrial dysfunction through a single therapeutic agent
Data Source
AI summary
Described herein are compositions and techniques related to generation and therapeutic application of cardiosphere-derived cells (CDCs) and CDC-derived exosomes. These cells and their secreted vesicles contain a unique milieu of biological factors, including cytokines, growth factors, transcription factors, nucleic acids including non-coding nucleic acids such as microRNAs, that serve to initiate and promote many therapeutic effects. Exosomes and their “cargo” contents, such as microRNAs can favorably modulate apoptosis, inflammation and fibrosis in the injured heart. Thus, CDC-derived exosomes represent a novel “cellfree” therapeutic candidate for tissue repair.